Presenter: Flavio Rocha, MD
Title of Presentation: Targeting BAP1 Mutations in Intrahepatic Cholangiocarcinoma
Summary of Presentation: There are no good biomarkers for the early diagnosis of cholangiocarcinoma. CEACAM6 is an extracellular protein involved in cell signaling. When overexpressed in gastrointestinal malignancies such as pancreas and colon cancer, it is associated with worse prognosis. Therefore we hypothesized that if CEACAM6 can be detected in the bile of patients of cholangiocarcinoma, it may serve as an early marker of disease. Bile was collected from patients undergoing resection for cholangiocarcinoma and from patients with benign biliary disease. Biliary CEACAM6 levels were determined by enzyme-linked immunosorbent assay and Western blot. Higher CEACAM6levels were found in the bile of patients with bile duct cancer especially extrahepatic cholangiocarcinoma. Future studies with a larger number of patients are needed to validate these results.